[go: up one dir, main page]

YU16899A - Aralkil i aralkiliden heterociklicni laktami i imidi - Google Patents

Aralkil i aralkiliden heterociklicni laktami i imidi

Info

Publication number
YU16899A
YU16899A YU16899A YU16899A YU16899A YU 16899 A YU16899 A YU 16899A YU 16899 A YU16899 A YU 16899A YU 16899 A YU16899 A YU 16899A YU 16899 A YU16899 A YU 16899A
Authority
YU
Yugoslavia
Prior art keywords
imides
aralkyl
heterocyclic lactams
compounds
formula
Prior art date
Application number
YU16899A
Other languages
English (en)
Inventor
Harry Ralph Howard
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Publication of YU16899A publication Critical patent/YU16899A/sh
Publication of RS49699B publication Critical patent/RS49699B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/96—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D267/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D267/02—Seven-membered rings
    • C07D267/08—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D267/10—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D273/00—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02—Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • C07D273/06—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/34—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/06—Seven-membered rings having the hetero atoms in positions 1 and 4 not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Opisano je jedinjenje formule (I) gde je R1 grupa formule G1, G2, G3, G4, G5, G6 ili G7; Y je proizvoljno supstituisani (C1-C4) heteroalkilni most koji zajedno sa atomima za koji je povezan formira pet- do sedmočlani heterocikl koji sadrži od dva do četiri heteroatoma, intermedijare za njihovo dobijanje i farmaceutske kompozicije koje sadrže ova jedinjenja. Ova jedinjenja su korisna kao psihoterapeutski agensi.[Compounds of the formula (I) wherein R1 is a group of formula G1, G2, G3, G4, G5, G6 or G7; Y is an optionally substituted (C1-C4) heteroalkyl bridge that, together with the atoms to which it is attached, forms a five to seven membered heterocycle containing two to four heteroatoms, intermediates for their preparation, pharmaceutical compositions containing them and their medicinal use. These compounds are useful as psychotherapeutic agents.
YUP-168/99A 1996-09-30 1997-09-08 Aralkil i aralkiliden heterociklični laktami i imidi RS49699B (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2711196P 1996-09-30 1996-09-30

Publications (2)

Publication Number Publication Date
YU16899A true YU16899A (sh) 2002-03-18
RS49699B RS49699B (sr) 2007-12-31

Family

ID=21835752

Country Status (45)

Country Link
US (6) US6380186B1 (sh)
EP (1) EP0929528B1 (sh)
JP (1) JP3121355B2 (sh)
KR (2) KR100346620B1 (sh)
CN (2) CN1239497C (sh)
AP (1) AP769A (sh)
AR (1) AR008861A1 (sh)
AT (1) ATE245630T1 (sh)
AU (1) AU732451B2 (sh)
BG (1) BG64484B1 (sh)
BR (1) BR9713239A (sh)
CA (1) CA2266107C (sh)
CO (1) CO4650135A1 (sh)
CZ (1) CZ295141B6 (sh)
DE (1) DE69723711T2 (sh)
DK (1) DK0929528T3 (sh)
DZ (1) DZ2321A1 (sh)
EA (1) EA002157B1 (sh)
ES (1) ES2202634T3 (sh)
GT (1) GT199700107A (sh)
HN (1) HN1997000135A (sh)
HR (1) HRP970540B1 (sh)
ID (1) ID19833A (sh)
IL (2) IL140623A (sh)
IS (1) IS4985A (sh)
MA (1) MA26443A1 (sh)
MY (1) MY125749A (sh)
NO (1) NO313192B1 (sh)
NZ (1) NZ334215A (sh)
OA (1) OA11002A (sh)
PA (1) PA8439101A1 (sh)
PE (1) PE2799A1 (sh)
PL (1) PL196005B1 (sh)
PT (1) PT929528E (sh)
RS (1) RS49699B (sh)
SA (2) SA05260293B1 (sh)
SI (1) SI0929528T1 (sh)
SK (1) SK284704B6 (sh)
TN (1) TNSN97161A1 (sh)
TR (1) TR199900660T2 (sh)
TW (1) TW491842B (sh)
UA (1) UA56185C2 (sh)
UY (1) UY24730A1 (sh)
WO (1) WO1998014433A1 (sh)
ZA (1) ZA978703B (sh)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування
US6423708B1 (en) * 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
EP0952154B1 (en) * 1998-04-16 2004-08-18 Pfizer Products Inc. N-acyl and N-aroyl aralkyl amides
HUP0201215A2 (en) * 1998-12-02 2002-08-28 Pfizer Prod Inc Methods and compositions for restoring conformational stability of a protein of the p53 family
EP1041070B1 (en) * 1999-03-30 2004-09-22 Pfizer Products Inc. Process for preparing cyclic thioamides
DE10022661A1 (de) * 2000-05-10 2001-11-15 Clariant Gmbh Ortho-substituierte Benzaldehyde, Verfahren zu ihrer Herstellung und ihre Verwendung
UA76130C2 (en) * 2000-11-20 2006-07-17 Merck Patent Gmbh Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
CA2443050A1 (en) * 2001-03-30 2002-10-10 Philadelphia Health And Education Corporation Immunomodulation and effect on cell processes relating to serotonin family receptors
ES2266416T3 (es) * 2001-08-30 2007-03-01 Pfizer Products Inc. Procedimiento para la preparacion de compuestos 2-(4-alquil-1-piperazinil)-benzaldehido y compuestos de -bencilidenilo por sustitucion nucleofila aromatica de 2-fluorobenzaldehido con 4-alquil-1-piperazina en agua como solvente.
EP1746091A1 (en) * 2001-08-30 2007-01-24 Pfizer Products Inc. Process for the preparation of 2-substituted 2-[-(4-methylpiperazin-1-yl)-benzylidene]-thiomorpholin-3-one citrate
US8575169B2 (en) 2001-10-29 2013-11-05 Versi Group, Llc Method of treating sexual dysfunctions with delta opioid receptor agonist compounds
CN100358878C (zh) * 2001-12-07 2008-01-02 辉瑞产品公司 治疗化合物的柠檬酸盐及其药物组合物
WO2004028480A2 (en) * 2002-09-30 2004-04-08 The Regents Of The University Of California Cystic fibrosis transmembrane conductance regulator protein inhibitors and uses thereof
US7235573B2 (en) * 2002-09-30 2007-06-26 The Regents Of The University Of California Methods of treating secretory diarrhea using cystic fibrosis transmembrane conductance regulator protein inhibitors
US7041693B2 (en) * 2002-10-04 2006-05-09 Bristol-Myers Squibb Company Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or TNF-α converting enzyme (TACE)
WO2005053701A1 (en) * 2003-11-26 2005-06-16 Pfizer Products Inc. Combination of dopamine agonists and aralkyl and aralkylidene heterocyclic lactams and imides
ATE473967T1 (de) * 2003-11-26 2010-07-15 Pfizer Prod Inc Aminopyrazolderivate als gsk-3-inhibitoren
CA2549308A1 (en) * 2003-12-15 2005-07-07 Pfizer Products Inc. Aralkyl and aralkylidene heterocyclic lactams with affinity for 5-ht1 receptors
US20050171095A1 (en) * 2004-01-06 2005-08-04 Pfizer Inc Combination of CRF antagonists and 5-HT1B receptor antagonists
US20050165025A1 (en) * 2004-01-22 2005-07-28 Recordati Ireland Ltd. Combination therapy with 5HT 1A and 5HT 1B-receptor antagonists
JP2007537151A (ja) * 2004-01-29 2007-12-20 ファイザー・プロダクツ・インク γ−アミノ酪酸モジュレータと５−ＨＴ１Ｂ受容体アンタゴニストとの組合せ
EA200601461A1 (ru) * 2004-03-17 2007-02-27 Пфайзер Продактс, Инк. Новые производные бензил(иден)лактама
EA200601798A1 (ru) 2004-04-30 2007-04-27 Уорнер-Ламберт Компани Ллс Замещенные соединения морфолина для лечения расстройств центральной нервной системы
JP2007537232A (ja) * 2004-05-11 2007-12-20 ファイザー・プロダクツ・インク 非定型抗精神病薬と５−ｈｔ１ｂ受容体拮抗薬の組合せ
WO2005113526A2 (en) * 2004-05-21 2005-12-01 Pfizer Products Inc. Metabolites of 4-(3,4-dichloro-phenyl)-2-[2-(4-methyl-piperazin-1-yl)-benzylidene]-thiomorpholin-3-one
CA2567483A1 (en) * 2004-05-21 2005-12-01 Pfizer Products Inc. Pyrazinylmethyl lactam derivatives
WO2006048727A1 (en) * 2004-11-02 2006-05-11 Pfizer Products Inc. Piperazinylphenalkyl lactam/amine ligands for the 5ht1b receptor
WO2006106416A1 (en) * 2005-04-08 2006-10-12 Pfizer Products Inc. PYRIDIL-LACTAMS AND THEIR USE 5 -HTl RECEPTORS LIGAN
WO2007026224A2 (en) * 2005-08-31 2007-03-08 Pfizer Products Inc. 5-ht1b antagonist composition for depression, anxiety and cognition
WO2007026219A2 (en) * 2005-08-31 2007-03-08 Pfizer Products Inc. Combinations of a 5-ht1b antagonist with a noradrenalin re-uptake inhibitor or a serotonin noradrenalin reutake inhibitor for treating cns conditions
WO2007057742A2 (en) * 2005-11-18 2007-05-24 Pfizer Products Inc. Novel piperazinone derivatives
GB0701970D0 (en) * 2007-02-01 2007-03-14 Wilson Stuart Treatment of protein aggregation diseases
AU2008299921B2 (en) 2007-09-13 2012-03-01 Concert Pharmaceuticals, Inc. Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof
EP2279029A2 (en) * 2008-03-25 2011-02-02 The Regents of the University of California Water soluble small molecule inhibitors of the cystic fibrosis transmembrane conductance regulator
UY31952A (es) 2008-07-02 2010-01-29 Astrazeneca Ab 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim
MX367774B (es) * 2011-10-03 2019-09-04 Ogeda S A N-ACIL-5,6,7, (8-SUSTITUIDO)-TETRAHIDRO- [1,2,4] TRIAZOLO [4,3-a] PIRAZINAS QUIRALES, NOVEDOSAS, COMO ANTAGONISTAS SELECTIVOS DE RECEPTOR DE NK-3; COMPOSICIÓN FARMACÉUTICA, MÉTODOS PARA USO EN TRASTORNOS MEDIADOS POR RECEPTOR DE NK-3 Y SU SÍNTESIS QUIRAL.
US10154988B2 (en) 2012-11-14 2018-12-18 The Johns Hopkins University Methods and compositions for treating schizophrenia
DE102013019618B4 (de) * 2013-11-25 2024-08-29 Avlen Georges Tri- und Tetracyclische Verbindungen zur Behandlung von Inkontinenz
WO2020183011A1 (en) 2019-03-14 2020-09-17 Institut Curie Htr1d inhibitors and uses thereof in the treatment of cancer
CN110054597B (zh) * 2019-04-17 2022-11-08 温州大学 一种无金属催化剂条件下合成的噻唑烷-4-酮衍生物及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6229570A (ja) 1985-07-29 1987-02-07 Kanegafuchi Chem Ind Co Ltd ３，５−ジイソプロピルベンジリデン複素環式化合物
HU199134B (en) 1987-12-14 1990-01-29 Richter Gedeon Vegyeszet Process for producing new 2,3-thiomorpholinedine-2-oxime derivatives and pharmaceutical compositions comprising same
IE62214B1 (en) * 1988-05-25 1995-01-11 Warner Lambert Co Arylmethylenyl derivatives of thiazolidinones, imidazolidinones and oxazolidinones useful as antiallergy agents and antiinflammatory agents
US5216002A (en) 1989-12-21 1993-06-01 Eli Lilly And Company Method of treating inflammatory bowel disease
DE4119757A1 (de) * 1991-06-15 1992-12-17 Basf Ag Aminoalkylsubstituierte thiazolin-2-one, ihre herstellung und verwendung
CA2099233A1 (en) * 1992-06-29 1993-12-30 Conrad P. Dorn Morpholine and thiomorpholine tachykinin receptor antagonists
DE69427289T2 (de) * 1993-03-16 2001-09-06 Pfizer Inc., New York Naphtalinderivate
US5556841A (en) 1994-02-04 1996-09-17 Santen Pharmaceutical Co., Ltd. Thiazine or thiomorpholine derivatives
GB9410512D0 (en) 1994-05-25 1994-07-13 Smithkline Beecham Plc Novel treatment
DE69523595T2 (de) * 1994-06-29 2002-06-27 Pfizer Inc., New York Aryl und heteroaryl alkoxynaphtalen derivate
JP3852787B2 (ja) 1995-06-01 2006-12-06 久光製薬株式会社 チオモルホリン誘導体
EP0779282A1 (en) * 1995-12-14 1997-06-18 Eli Lilly And Company Thiomorpholinone compounds for treating multiple sclerosis
DE69733996T2 (de) 1996-03-29 2006-07-20 Pfizer Inc. Benkyl(idene)-lactam-derivate, deren herstellung und verwendung als selektive (ant)agonisten von 5-ht1a- und/oder 5-ht1d rezeptoren
US6423708B1 (en) * 1996-09-30 2002-07-23 Pfizer Inc Aralkyl and aralkylidene heterocyclic lactams and imides
UA56185C2 (uk) * 1996-09-30 2003-05-15 Пфайзер Інк. Аралкіл- та аралкіліденгетероциклічні лактами та іміди, фармацевтична композиція та спосіб лікування

Also Published As

Publication number Publication date
CO4650135A1 (es) 1998-09-03
US20020147194A1 (en) 2002-10-10
ZA978703B (en) 1999-03-30
CN1239497C (zh) 2006-02-01
CZ107199A3 (cs) 2000-05-17
TW491842B (en) 2002-06-21
NO991525L (no) 1999-05-28
CN1093123C (zh) 2002-10-23
US6403592B1 (en) 2002-06-11
CA2266107C (en) 2002-12-03
IL129045A0 (en) 2000-02-17
NO313192B1 (no) 2002-08-26
BG103297A (en) 1999-11-30
PL196005B1 (pl) 2007-11-30
SI0929528T1 (en) 2003-10-31
MY125749A (en) 2006-08-30
KR100323167B1 (ko) 2002-02-04
ES2202634T3 (es) 2004-04-01
PL332629A1 (en) 1999-09-27
IL140623A0 (en) 2002-02-10
US6562813B2 (en) 2003-05-13
HN1997000135A (es) 1998-01-28
AR008861A1 (es) 2000-02-23
US6472388B2 (en) 2002-10-29
PA8439101A1 (es) 2000-05-24
KR100346620B1 (ko) 2002-07-26
GT199700107A (es) 1999-03-23
US20020091119A1 (en) 2002-07-11
DK0929528T3 (da) 2003-10-06
BR9713239A (pt) 2000-04-04
TR199900660T2 (xx) 1999-07-21
RS49699B (sr) 2007-12-31
US6921760B2 (en) 2005-07-26
OA11002A (en) 2001-11-06
TNSN97161A1 (fr) 2005-03-15
MA26443A1 (fr) 2004-12-20
PT929528E (pt) 2003-12-31
SK284704B6 (sk) 2005-09-08
BG64484B1 (bg) 2005-04-30
DZ2321A1 (fr) 2002-12-28
US20020091118A1 (en) 2002-07-11
DE69723711T2 (de) 2004-02-05
CZ295141B6 (cs) 2005-05-18
EA199900242A1 (ru) 1999-08-26
HRP970540B1 (en) 2002-08-31
HRP970540A2 (en) 1998-08-31
ID19833A (id) 1998-08-06
PE2799A1 (es) 1999-02-04
UA56185C2 (uk) 2003-05-15
CN1231661A (zh) 1999-10-13
CA2266107A1 (en) 1998-04-09
EP0929528B1 (en) 2003-07-23
SA05260293B1 (ar) 2006-04-18
UY24730A1 (es) 2000-09-29
HK1022313A1 (en) 2000-08-04
AP9701107A0 (en) 1997-10-31
AU3951497A (en) 1998-04-24
IL129045A (en) 2005-09-25
JP3121355B2 (ja) 2000-12-25
CN1329002A (zh) 2002-01-02
NZ334215A (en) 2000-09-29
AU732451B2 (en) 2001-04-26
WO1998014433A1 (en) 1998-04-09
SA97180449A (ar) 2005-12-03
KR20000048731A (ko) 2000-07-25
US20020072519A1 (en) 2002-06-13
AP769A (en) 1999-09-30
JP2000503679A (ja) 2000-03-28
EP0929528A1 (en) 1999-07-21
IS4985A (is) 1999-02-26
DE69723711D1 (de) 2003-08-28
IL140623A (en) 2005-03-20
US20020091117A1 (en) 2002-07-11
NO991525D0 (no) 1999-03-29
ATE245630T1 (de) 2003-08-15
SA97180449B1 (ar) 2005-12-21
US6380186B1 (en) 2002-04-30
SK41099A3 (en) 2000-09-12
EA002157B1 (ru) 2001-12-24
US6627627B2 (en) 2003-09-30

Similar Documents

Publication Publication Date Title
YU16899A (sh) Aralkil i aralkiliden heterociklicni laktami i imidi
AU1120599A (en) New heterocyclic compounds and their use in medicine, process for their reparation and pharmaceutical compositions containing them
EA200200708A1 (ru) Производные бензазола и их применение в качестве модуляторов jnk
WO2002051819A3 (en) Heterocyclic compounds having antibacterial activity, process for their preparation and pharmaceutical compositions containing them
DK0958296T3 (da) Heterocykliske forbindelser, fremgangsmåde til deres fremstilling og farmaceutiske præparater, der indeholder dem, og deres anvendelse i behandlingen af diabetes og beslægtede sygdomme
IL129409A0 (en) 1-Phenylpyrazole compounds and pharmaceutical compositions containing the same
YU34896A (sh) Supstituisani n-(indol-2-karbonil)-glicinamidi, njihovi intermedijeri i farmaceutske kompozicije
DK0889877T3 (da) Meta-substituerede phenylenderivater og deres anvendelse som alfav-beta3-integrin-antagonister eller -inhibitorer
DK0894084T3 (da) Kanelsyrederivater og deres anvendelse som integrinantagonister
ATE302778T1 (de) N-substituierte 4-aminopteridine, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
ES2174298T3 (es) Derivados de aminotiazol, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
YU75101A (sh) Supstituisani biciklični heterocikli, postupak njihove izrade i njihova upotreba kao antigojaznih i hipoholesterolemijskih agenasa
NZ210100A (en) 5h,11h-pyrrolo(2,1-c)(1,4)benzoxazepine derivatives and pharmaceutical compositons
NZ516100A (en) Streptogramin derivatives, preparation and compositions containing them
IL125982A0 (en) 2-(arylphenyl) amino-imidazoline derivatives
NO963331L (no) 5-Heteroarylindol-derivater som benzodiazepin-reseptorsete-agonister og antagonister
NO960441L (no) Benzopyraner og farmasöytiske forbindelser inneholdende dem
EP1019047A4 (en) ANTITHROMBOTIC AGENTS
DE69330601D1 (de) Serotoninergische ergolin derivate
NO983444D0 (no) Benzo(c)kinolizin derivater, deres fremstilling og anvendelse som 5<alfa>-reduktaseinhibitorer
DK0541263T3 (da) 5-Piperazinylalkyl-1,5-benzothiazepinoner, der er nyttige som calciumantagonister
ES2132245T3 (es) Derivados de 1-azaadamantano como agonistas o antagonistas de 5-ht.
IL115791A0 (en) Heterocycle substituted propenoic acid derivatives and pharmaceutical compositions thereof
ES2058182T3 (es) Analogos de mitomicina. un procedimiento para su preparacion y composiciones farmaceuticas.
WO2005061491A3 (en) Aralkyl and aralkylidene heterocyclic lactams with affinity for 5-ht1 receptors